Table 1. Clinical characteristics of NFC and IPF patients.
Characteristic | IPF (N=9) | Non Fibrotic (N=8) |
---|---|---|
Sex (no. of subjects) | ||
Male | 8 (90%) | 3 (37.5%) |
Female | 1 (10%) | 5 (62.5) |
Age (yr) | ||
Mean ( ± SEM) | 59.77 ± 3.39 | 69.5 ± 3.3 |
Range | 40 - 70 | 58 - 80 |
Length of symptoms (yrs) | ||
Mean ( ± SEM) | 4.86 ± 1.38 | NA |
Range | 1 - 11 | NA |
Smoking (no. with >10 pack/years) | 7 | 5 |
FEV1 (% predicted ± SEM) | 39.56 ± 3.675 | 112.9 ± 11.04 |
FVC (% predicted ± SEM) | 45.63 ± 6.074 | 92.54 ± 10.51 |
DLCO (% predicted ± SEM) | 26.63 ± 3 | ND |
PA mean (% predicted ± SEM) | 28.38 ± 2.57 | ND |
Treatments | ||
Prednisone | 7 | 0 |
Mycophenolate Mofetil | 5 | 0 |
Azathioprine | 2 | 0 |
Methylprednisolone sodium succinate | 2 | 0 |
Tacrolimus | 2 | 0 |
This table shows the clinical characteristics of the human lung myofibroblasts isolated from both the NFC (n=8) and IPF (n=9) donors. Key; NA – Not applicable, ND- Not done.